IQVIA posts strong Q2 with 8.7% revenue growth and 19% surge in R&D bookings, rating Buy.

IQVIA Holdings reported solid Q2 results with revenue up 8.7% to $4.37 billion and adjusted EPS rising 12.1%. The company saw a 19% increase in R&D net new bookings to $3.15 billion, driven by growth in its Commercial Solutions segment, which grew 8.6% aided by AI adoption and data assets. Despite strong performance, risks include over $14 billion in debt and a valuation near 20 times 2026 EPS. The base case price target is set between $285 and $305, supporting a Buy rating.

IQVIA Holdings shares trade at USD 268.51 on Pluang as of Oct 20, 2026 22:41 WIB, close to their 52-week high of USD 275.02. The stock has gained 0.99% in the last day, despite all recent Pluang order activity being sell orders. The company’s market cap stands at $43.76 billion, reflecting its significant presence in the health sector.